padcev
(ENFORTUMAB VEDOTIN)SEAGEN INC.
Usage: PADCEV® is indicated for adults with locally advanced or metastatic urothelial cancer (mUC). It can be used in combination with pembrolizumab or as a single agent for patients who have previously received PD-1/PD-L1 inhibitors and platinum-based chemotherapy, or are ineligible for cisplatin-containing chemotherapy.